05 February 2013 - Geneva - Community activists are gathering in Geneva this week to agree on the steps required to achieve greater community engagement in the fight against tuberculosis (TB).

NEW DELHI—For the first time, five emerging-market nations with extensive infectious-disease problems—Brazil, Russia, India, China and South Africa—have agreed to work together to fight an epidemic of drug resistance in tuberculosis.

Vaccine candidate was generally well tolerated, meeting the study’s primary objective of safety; Vaccine candidate did not provide statistically-significant protection in preventing TB disease in infants previously vaccinated with BCG.

Huge increases in funding for international health over the past two decades have led to a proliferation of donors, partnerships, and health organisations. Over the same period, the global burden of non-communicable diseases has increased absolutely and relative to communicable diseases. In this changing landscape, national programmes for the control of HIV/AIDS, tuberculosis, malaria, and neglected tropical diseases must be reinforced and adapted for three reasons: the global burden of these communicable diseases remains enormous, disease control programmes have an integral and supporting role in developing health systems, and the health benefits of these control programmes go beyond the containment of specific infections. WHO's traditional role in promoting communicable disease control programmes must also adapt to new circumstances. Among a multiplicity of actors, WHO's task is to enhance its normative role as convenor, coordinator, monitor, and standard-setter, fostering greater coherence in global health.

Geneva – A world-first online resource has been launched to help strengthen the ability of healthcare systems in developing countries respond to AIDS, tuberculosis and malaria.

After nearly 100 years, researchers could be on the verge of finding a vaccine that would eradicate tuberculosis infections, a scourge that kills 1.4 million people a year.

Australian infectious disease therapy and vaccine development company BioDiem Ltd has detailed a new phase of research to assess its novel antimicrobial BDM-I as a treatment for tuberculosis** (TB), and fungal* infections.

Fixed-dose combination (FDC) formulations simplify TB therapy but are not better for patients, a recent meta-analysis reports.

BUFFALO, N.Y. – A new pathway for improving vaccines against tuberculosis has been discovered by microbiologists at the University at Buffalo in collaboration with researchers at other universities, according to a paper in the journal Mucosal Immunology, published by the Nature group.

The European Commission (EC) released on 29 June 2011 a budget proposal for 2014-2020, where €70 billion is allocated to the heading “Global Europe,” which covers the European Union (EU)’s operating plan in the world, including development and humanitarian aid. However, the latest draft proposal laid down by Council President Herman Van Rompuy sharply cuts back development aid and humanitarian assistance by almost €10 billion, to €60.6 billion.